Literature DB >> 18448502

Determinants of hospital costs in community-acquired pneumonia.

S Reyes1, R Martinez, J M Vallés, E Cases, R Menendez.   

Abstract

Community-acquired pneumonia (CAP) has a high incidence and involves an important consumption of healthcare resources. The present authors analysed the influence of comorbidity, initial severity and complications upon the direct costs associated with hospitalised CAP patients. Direct hospitalisation costs (room cost, treatment, laboratory and diagnostic tests) were assessed in a prospective, observational study of 271 patients admitted to a hospital ward due to CAP. The mean+/-SD patient age was 70+/-15 yrs. The mortality rate was 11.1%. Complications were found in 72.3% and comorbidities in 74.9%. The median (interquartile range) total cost was 1,683 euros (1,291-2,471 euros) and the component costs were: room cost 1,286 euros (857-1,714 euros); laboratory tests 212 euros (171-272 euros); treatment 187 euros (114-304 euros); and diagnostic procedures 58 euros (29-122 euros). Complications and higher Pneumonia Severity Index increased the costs, but age and comorbidity did not. A logistic regression analysis to predict high cost (>1,683 euros) showed that infectious (odds ratio 6.8, 95% confidence interval 1.3-36), digestive (5.9 (1.5-22.8)), pulmonary (2.6 (1.4-4.7)) and other complications (3.9 (1.8-8.4)) were independent risk factors, as were previous hospitalisation (2.3 (1.2-4.3)) and hypoalbuminaemia (2 (1.1-3.6)). Complications, hypoalbuminaemia and previous hospitalisation were the main determinants of high direct costs of hospitalisation due to community-acquired pneumonia. Neither age nor comorbidities were independently associated with cost.

Entities:  

Mesh:

Year:  2008        PMID: 18448502     DOI: 10.1183/09031936.00083107

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  Hospital Treatment Costs and Factors Affecting These Costs in Community-Acquired Pneumonia.

Authors:  Fatma Tokgöz Akyıl; Armağan Hazar; İpek Erdem; Canan Pehlivan Öneş; Murat Yalçınsoy; İlim Irmak; Umut Sabri Kasapoğlu
Journal:  Turk Thorac J       Date:  2015-07-01

2.  Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP.

Authors:  Marie-Josée J Mangen; Marc J M Bonten; G Ardine de Wit
Journal:  BMC Infect Dis       Date:  2013-12-19       Impact factor: 3.090

3.  Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective.

Authors:  Keiko Konomura; Hideaki Nagai; Manabu Akazawa
Journal:  Pneumonia (Nathan)       Date:  2017-12-05

4.  The impact of community-acquired pneumonia on the health-related quality-of-life in elderly.

Authors:  Marie-Josée J Mangen; Susanne M Huijts; Marc J M Bonten; G Ardine de Wit
Journal:  BMC Infect Dis       Date:  2017-03-14       Impact factor: 3.090

5.  Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain).

Authors:  Antoni Sicras-Mainar; Jordi Ibáñez-Nolla; Isabel Cifuentes; Pablo Guijarro; Ruth Navarro-Artieda; Lorenzo Aguilar
Journal:  BMC Infect Dis       Date:  2012-11-01       Impact factor: 3.090

6.  Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults.

Authors:  Daniel Polsky; Machaon Bonafede; Jose A Suaya
Journal:  BMC Health Serv Res       Date:  2012-10-31       Impact factor: 2.655

7.  Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study.

Authors:  Helmut Ostermann; Javier Garau; Jesús Medina; Esther Pascual; Kyle McBride; Francesco Blasi
Journal:  BMC Pulm Med       Date:  2014-03-05       Impact factor: 3.317

8.  Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis.

Authors:  Simone M C Spoorenberg; Willem Jan W Bos; Rik Heijligenberg; Paul G P Voorn; Jan C Grutters; Ger T Rijkers; Ewoudt M W van de Garde
Journal:  BMC Infect Dis       Date:  2014-06-17       Impact factor: 3.090

Review 9.  Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.

Authors:  Antoni Torres; Francesco Blasi; Nathalie Dartois; Murat Akova
Journal:  Thorax       Date:  2015-07-28       Impact factor: 9.139

10.  Burden of community-acquired pneumonia in adults over 18 y of age.

Authors:  Filiz Kosar; Devrim Emel Alici; Basak Hacibedel; Burcu Arpınar Yigitbas; Pejman Golabi; Caglar Cuhadaroglu
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.